1 results match your criteria: "and Yancheng Center for Disease Control and Prevention[Affiliation]"
Long-term efficacy of a hepatitis E vaccine.
N Engl J Med
March 2015
From the State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University (J.Z., S.-J.H., T.W., J.W.-K.S., M.-H.N., N.-S.X.), and Xiamen Innovax Biotech Company (Q.Y., M.G., X.-H.L., H.-R.P., Y.-M.L.), Xiamen, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing (X.-F.Z., Y.-M.H., H.W., J.-X.L., F.-C.Z.), Dongtai Center for Disease Control and Prevention, Dongtai (Z.-Z.W., H.-M.J., Y.-J.W., C.-L.Y.), and Yancheng Center for Disease Control and Prevention, Yancheng (Q.T., R.-J.J.) - all in China.
Background: Hepatitis E virus (HEV) is a leading cause of acute hepatitis. The long-term efficacy of a hepatitis E vaccine needs to be determined.
Methods: In an initial efficacy study, we randomly assigned healthy adults 16 to 65 years of age to receive three doses of either a hepatitis E vaccine (vaccine group; 56,302 participants) or a hepatitis B vaccine (control group; 56,302 participants).